Editas Medicine (EDIT) Posts Smaller Q2 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. FIS
5. BROS
6. QCOM
7. DDOG
8. EW
9. ZG
10. W

Go back to Editas Medicine (EDIT) Posts Smaller Q2 Loss

Editas Medicine Announces Second Quarter 2020 Results and Update

August 6, 2020 4:06 PM EDT

Regained full control of ocular medicines under new agreement with AbbVie

BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of 2020

Plan to file IND for EDIT-301 for sickle cell disease by end of 2020

Strengthened balance sheet through equity offering raising $216 million in gross proceeds

Cash, cash equivalents, and marketable securities of $599 million as of June 30, 2020

CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq:... More